Iterum Therapeutics plc
Iterum Therapeutics plc (ITRM): 2 pipeline candidates · ~5 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
4.8 months
D/E -5.40
Lead: Approved
2 candidates
N/A
N/A
A transparent, data-derived signal for Iterum Therapeutics plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.6M
Cash
$11.0M
Quarterly Burn
$7.4M
Runway
4.8 mo
Revenue
$390K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in Iterum Therapeutics plc's pipeline?
Iterum Therapeutics plc (ITRM) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Iterum Therapeutics plc's lead drug candidate?
Iterum Therapeutics plc's most advanced tracked candidate is orlynvah (Approved) for uncomplicated urinary tract infections (uUTI) in adult women caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options.
What is Iterum Therapeutics plc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Iterum Therapeutics plc has approximately 4.8 months of cash runway.
What is Iterum Therapeutics plc's market capitalization?
Iterum Therapeutics plc's market capitalization is approximately $1.6M.
Who is the CEO of Iterum Therapeutics plc?
Mr. Corey N. Fishman is the chief executive officer of Iterum Therapeutics plc (ITRM).
Get the full picture on Iterum Therapeutics plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.